Atypical psoriasis following rituximab for rheumatoid arthritis.

New onset of psoriasis in a patient with rheumatoid arthritis treated with rituximab.

Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab.

Sir, Anti-tumour necrosis factor alpha (TNF-α) agents, such as infliximab, adalimumab and etanercept, are remarkably effective in the treatment of rheumatoid arthritis (RA), Crohn's disease and psoriasis vulgaris (1–4). Recent case reports have described the treatment of hidradenitis suppurativa (5) and acne conglobata (6) with infliximab. Regardless of the dramatic improvement in symptoms, it ...

Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study

BACKGROUND The relative cost of biologics in the treatment of autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis, is a key consideration for managed care payers. OBJECTIVES Our objective was to estimate biologic costs and treatment patterns in US managed care patients with rheumatoid arthritis, psoriatic arthritis, psoriasis, and/o...

بررسی مقایسه ای فراوانی بروز ضایعات دهانی در بین بیماران پسوریازیس و روماتویید آرتریت؛ یک گزارش کوتاه

Introduction: According to previous studies, the prevalence of oral lesions in patients with psoriasis is on the rise. But precise knowledge of the prevalence among Iranian patients is not available. The aim of this study was to evaluate of oral lesions between psoriatic patients and comparing by past results. Materials and methods: Present descriptive-analytic study is done on psoriatic pat...

Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis

The chimeric anti-CD20 monoclonal antibody rituximab has been used extensively in the treatment of B cell malignancies, and more recently it has emerged as a potential treatment for rheumatoid arthritis (RA), via selective B lymphocyte depletion. Experience in oncology shows that rituximab is well tolerated in a variety of settings, with mild-to-moderate infusion related reactions following the...